Publikation

Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry

Wissenschaftlicher Artikel/Review - 01.08.2005

Bereiche
PubMed
DOI

Zitation
Brouwers E, Tibben M, Jörger M, van Tellingen O, Rosing H, Schellens J, Beijnen J. Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry. Analytical and bioanalytical chemistry 2005; 382:1484-90.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Analytical and bioanalytical chemistry 2005; 382
Veröffentlichungsdatum
01.08.2005
ISSN (Druck)
1618-2642
Seiten
1484-90
Kurzbeschreibung/Zielsetzung

A method for sensitive determination of the anti-cancer agent oxaliplatin in human plasma and human plasma ultrafiltrate (pUF) is presented. The method is based on the quantification of platinum by graphite-furnace atomic-absorption spectrometry, with Zeeman correction and an atomisation temperature of 2,700 degrees C. Sample pretreatment involves dilution of the samples with a solution containing 0.15 mol L(-1) NaCl and 0.20 mol L(-1) HCl in water. Validation was performed in accordance with the most recent FDA guidelines for bioanalytical method validation. All results were within requirements. The validated ranges of quantification were 0.10-400 micromol L(-1) for human pUF and 0.50-400 micromol L(-1) for plasma. The assay is now successfully used to support pharmacokinetic studies of cancer patients treated with oxaliplatin.